コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 1/2, human herpesvirus 8, hepatitis E virus, parvovirus B19).
2 virus, rubella, measles, papillomavirus, and parvovirus B19.
3 hrovirus and is closely related to the human parvovirus B19.
4 a highly efficient systemic dissemination of parvovirus B19.
5 s and allow beta1 integrin-mediated entry of parvovirus B19.
6 een reported to be the cellular receptor for parvovirus B19.
7 reported to be the cell surface receptor for parvovirus B19, a number of nonerythroid cells, which ex
8 ere detected in EMBs from 37 (39%) patients; parvovirus B19, adenovirus, and Epstein-Barr virus (EBV)
10 recent studies investigating the presence of parvovirus B19 and herpesviruses in temporal arteries wi
11 d confirmatory study, livers were tested for parvovirus B19 and its variant erythroviruses, V9 and A6
12 wo human parvoviruses, namely the pathogenic parvovirus B19 and the nonpathogenic adeno-associated vi
14 ing three invasive Group A streptococci, two parvovirus B19, and one each of HIV-1, measles virus, My
15 and therapeutic utility of the knowledge of parvovirus B19 as the likely etiologic link between the
16 antibodies to nonstructural protein NS-1 in parvovirus B19-associated arthritis have been detected.
17 hat of Aleutian mink disease virus and human parvovirus B19, autonomous members of the genus, despite
24 We evaluated the prevalence of persistent parvovirus B19 (B19) infection and associated anemia in
28 ive Finnish casualties from World War II for parvovirus B19 (B19V) DNA, and found a remarkable preval
33 lates viral DNA replication.IMPORTANCE Human parvovirus B19 (B19V) infection causes hematological dis
46 ng of the precursor mRNA (pre-mRNA) of human parvovirus B19 (B19V) plays a key role in posttranscript
49 em has limited high-resolution structures of parvovirus B19 (B19V) to virus-like particles (VLPs).
50 irus 1 (HSV-1), human herpesvirus 6 (HHV-6), parvovirus B19 (B19V), BK polyomavirus (BKPyV), human ad
51 more conformational antigens to detect human parvovirus B19 (B19V)-specific immunoglobulin M (IgM) or
54 e documented that P antigen is necessary for parvovirus B19 binding but not sufficient for virus entr
57 s the potential as an effective antiviral of parvovirus B19 caused hematological disorders, as well a
60 rus, Toxoplasma gondii, rubella virus, human parvovirus B19, Chlamydia trachomatis, or human papillom
63 ns (such as syphillis, varicella-zoster, and parvovirus B19), cytomegalovirus, and herpes simplex vir
64 oinfection with HBV, and 1 case each of HBV, parvovirus B19, cytomegalovirus, and human herpesvirus 7
66 isco, Calif.) for real-time PCR detection of parvovirus B19 DNA by retesting 71 specimens previously
68 significant difference in the prevalence of parvovirus B19 DNA in livers from patients with FH or HA
71 antigen is necessary but not sufficient for parvovirus B19 entry into cells, and (iv) parvovirus B19
72 562 cells become adherent and permissive for parvovirus B19 entry, which is mediated by alpha 5 beta
73 llowed us to reconstruct three ancient human parvovirus B19 genomes and one ancient human hepatitis B
78 gene polymorphisms have been associated with parvovirus B19, hepatitis C virus, HIV-1/AIDS infection,
80 er rash-causing infections, such as measles, parvovirus B19, human herpesvirus 6, and enteroviruses i
83 temporary genotypes of hepatitis B virus and parvovirus B19 in ancient human remains demonstrate that
84 gnostic assays, we discovered an outbreak of parvovirus B19 in dengue-suspected patients that occurre
87 her examine the role of the host response to parvovirus B19 in the development of symptoms and conseq
88 mens from individuals with lupus (n = 16) or parvovirus B19 infection (n = 6) or specimens containing
89 ate to combat B19V infection.IMPORTANCEHuman parvovirus B19 infection causes severe hematological dis
94 e VP1 has a high efficiency in inhibition of parvovirus B19 infection of human erythroid progenitors,
95 oglobulin (IVIg) in the treatment of chronic parvovirus B19 infection, this therapy can cure some of
96 e development of symptoms during acute human parvovirus B19 infection, we compared human leukocyte an
100 measured in the sera of patients with acute parvovirus B19 infections (n = 12), in those with other
101 n HLA-A*2402-positive individuals with acute parvovirus B19 infections made vigorous CD8-positive cyt
103 e neighboring VP2 capsid proteins.IMPORTANCE Parvovirus B19 is a common human pathogen and a particul
114 cluding human papillomavirus 16 (HPV-16) and parvovirus B19 (PB-19), with a picomolar sensitivity.
115 ly 0.1% of fetal losses were attributable to parvovirus B19 positivity, a proportion which could incr
117 Expression of globotetraosylceramide, the parvovirus B19 receptor, on myeloblasts may also explain
122 capsids, or virus-like particles (VLPs), of parvovirus B19 that carry dengue 2-specific epitopes wer
126 of cell types and is involved in binding of parvovirus B19 to human cells, (ii) the level of P antig
127 ide direct evidence regarding the ability of parvovirus B19 to induce invasive properties in normal h
128 everse-transcriptase PCR for the presence of parvovirus B19 transcripts as a marker of viral replicat
130 biopsy, explant, or autopsy was analyzed for parvovirus B19 using primers designed to amplify a 699-b
133 s of infection with hepatitis B virus (HBV), parvovirus B19, variola virus (VARV), and Mycobacterium
134 or parvovirus B19 entry into cells, and (iv) parvovirus B19 vectors can be used to transduce HUVEC an
135 ave described the development of recombinant parvovirus B19 vectors with which high-efficiency, eryth
136 an enzyme immunoassay that detects the human parvovirus B19 virus (B19V) immunoglobulin M (IgM) or Ig
137 pectrum of the acute polyarthritis caused by parvovirus B19 was further delineated and was shown to i
138 rospective Southern analyses to detect human parvovirus B19 was performed in the 27 patients for whom
139 Human erythrovirus genotype 1 (formerly parvovirus B19) was prevalent in the United Kingdom, Mal